Appclon "All-out effort to develop COVID-19 antibodies... Speed is the top priority"

[Asia Economy Reporter Hyunseok Yoo] Antibody specialist company Abclon announced that it has formed a TF team and is concentrating its internal research and development capabilities to rapidly derive therapeutic antibodies that neutralize the novel coronavirus infection (COVID-19) virus.

A company official stated, "To swiftly respond to the unprecedentedly severe impact of the COVID-19 virus threat on human society and the economy, we are putting all our efforts into research and development for the early derivation of therapeutic antibodies. Starting next week, we plan to conduct qualification tests on antibody samples that can be secured first, and will continuously develop additional candidate antibodies sequentially," he explained.

During this period, Abclon plans to fully concentrate the technologies it has built together with its Swedish partners, including its proprietary antibody library, affibody library, and humanized antibody technology.

Additionally, the company conveyed a strong commitment to COVID-19 drug development, stating, "Depending on the results, we are preparing to immediately start cell line development and preclinical animal testing from this month." To this end, consultations with domestic antibody CMOs are planned, and discussions with relevant agencies for rapid clinical trials are also underway.

Abclon's COVID antibody TF team is a special organization composed of excellent development team members from existing pipelines, aiming to maximize synergy by combining international antibody drug co-development experience and know-how, including Sweden, with the full capabilities of its independent antibody platform expert team.

Furthermore, the originally planned goals such as "the first domestic clinical entry of CAR-T" and "technology transfer of the bispecific antibody pipeline" are being pursued without change, ensuring that there will be no disruption to the subsequent schedules of existing pipelines.

This content was produced with the assistance of AI translation services.